A5065854286- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Eosinophilic Esophagitis
- Migraine and Headache Studies
- Ophthalmology and Eye Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Diversity and Career in Medicine
- Olfactory and Sensory Function Studies
- Mycobacterium research and diagnosis
- Cardiac, Anesthesia and Surgical Outcomes
- Acute Ischemic Stroke Management
- Colorectal Cancer Screening and Detection
- Appendicitis Diagnosis and Management
- Autoimmune and Inflammatory Disorders
- Trigeminal Neuralgia and Treatments
- Vaccine Coverage and Hesitancy
- Abdominal Trauma and Injuries
- Liver Disease Diagnosis and Treatment
- Celiac Disease Research and Management
- Venous Thromboembolism Diagnosis and Management
- Hepatitis C virus research
AbbVie (United States)
2024-2025
AbbVie (Japan)
2024-2025
Takeda (United States)
2021-2024
University of Illinois Chicago
2024
MCPHS University
2020-2022
Boston University
2022
Abstract Objective To evaluate unmet needs among individuals with episodic migraine (EM) in the United States (US). Background Data are limited on impact of headache frequency (HF) and preventive treatment failure (TF) burden US. Methods A retrospective, cross‐sectional analysis 2019 National Health Wellness Survey (NHWS) data was conducted from an opt‐in online survey that identified respondents (aged ≥18 years) US self‐reported physician‐diagnosed migraine. Participants were stratified by...
Patients with inflammatory bowel disease (IBD) may receive multiple successive biologic treatments in clinical practice; however, data are limited on the comparative effectiveness of biologics and impact treatment sequence outcomes.
Crohn's disease (CD) is a chronic inflammatory bowel characterized by relapsing and remitting inflammation that leads to progressive damage. Despite advances in medical treatment for CD, many patients require surgical intervention. Most studies of surgery rates are from treated with anti-tumor necrosis factor alpha (anti-TNFα) treatments, comparatively little data on the vedolizumab ustekinumab. SOJOURN aimed estimate hazard rate incidence first CD-related following initiation or ustekinumab...
To understand the real-world treatment switch rates of atogepant versus calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) using claims data from United States.
Dose escalation of biologics may regain treatment response in patients with ulcerative colitis (UC). However, dose rates and associated outcomes costs are not well characterized biologic-naïve receiving antitumor necrosis factor-alpha (anti-TNF-α) treatments, such as infliximab or adalimumab vedolizumab.ODESSA-UC, a retrospective cohort study investigating UC who had received first-line biologics, used data from IBM MarketScan databases. Adults ≥1 claim for an index drug (adalimumab,...
Patients with inborn errors of immunity (IEI) are predisposed to severe recurrent/chronic infections, and often require hospitalization, resulting in substantial burden patients/healthcare systems. While immunoglobulin replacement therapies (IgRTs) the standard first-line treatment for most forms IEI, limited real-world data exist regarding clinical characteristics costs patients IEI initiating such treatment. This retrospective analysis examined infection US IgRT immune globulin infusion...
Dose escalation of biologics may restore response in patients with Crohn's disease (CD) who experience inadequate or loss response, but the rates dose and subsequent adverse clinical outcomes have not been well characterized.
Abstract BACKGROUND In the real-world clinical setting, patients with moderate-to-severe ulcerative colitis (UC) may undergo dose escalation when they lose response to their prescribed biologic treatment. Such of agents has an impact on healthcare utilization and costs have patient outcomes. Currently, limited data exist that compare rates between anti-tumor necrosis factor (anti-TNF) therapies vedolizumab, a gut-selective integrin antagonist, in UC who not previously been treated (bio-naïve...
Abstract INTRODUCTION Following inadequate response, loss of or intolerance to a first-line biologic, patients with Crohn’s disease (CD) may switch treatment second-line biologic therapy. Data on the clinical outcomes receiving two more lines therapy are limited. We assessed adverse CD different sequences. METHODS ROTARY (Real-wOrld ouTcomes Across tReatment sequences in inflammatorY bowel patients) part B used data from Optum Clinical Database and included adult diagnosed who received at...
Abstract INTRODUCTION Inadequate response, loss of or intolerance to a first-line biologic typically requires patients with ulcerative colitis (UC) switch treatment second-line therapy. However, the clinical outcomes receiving different sequences are poorly understood. We assessed adverse sequences. METHODS ROTARY (Real wOrld ouTcomes Across tReatment in inflammatorY bowel disease patients) part B used data from Optum Clinical Database and included adult diagnosed UC who received at least...